课题基金 / 基金详情

A Lexicon of Stapled Peptide Helices Engineered to Capture the Protein Interactom

A Lexicon of Stapled Peptide Helices Engineered to Capture the Protein Interactom
旨在捕获蛋白质相互作用的钉合肽螺旋词典
批准号:
7937806
负责人:
Loren David Walensky
金额:
$43.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2014-08-31

项目摘要

项目成果

Loren David Walensky的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Whether fleeting or stable, normal or aberrant, protein interactions and their sites of contact form the basis for discovery of biological pathways, disease mechanisms, and opportunities for therapeutic intervention. The goal of this proposal is to intertwine chemistry, biology, and medicine to create a transformative high- throughput technology that precisely identifies protein targets and their explicit sites of interaction. Like the teeth of a key that perfectly fit into a lock, complementary protein shape is critical to the execution of biological interactions. The molecular handshakes of proteins rely on their discrete substructures and these contact points are typically embedded within a complex protein that provides the infrastructure to maintain the essential bioactive fold. Ideally, these evolutionarily honed substructures could be used to capture and thereby catalogue their protein targets; however, out of context from the whole protein, bioactive subdomains often unfold, resulting in loss of biological shape, potency, and specificity. To reclaim the enormous capacity of structured peptides to selectively bind and capture their protein targets, we will first restore their bioactive shape and then chemically derivatize them for both non-covalent and covalent capture. In this proposal, we focus on the peptide 1-helix, arguably the most ubiquitous and versatile biological shape harnessed by the cell. We will apply our robust "hydrocarbon stapling" technology to synthesize a diversity of bioactive 1-helices and then chemically install new immobilization and intercalating functionalities to expand our grasp of the interactome by trapping the full-range of stable to transient protein interactors. Our covalent capture chemistry and proteomic analyses afford a two-for-one advantage: identification of protein targets and their sites of interaction. Since protein interaction sites are the topographic templates for drug design, we believe that the binding site identification feature of our approach will provide a critical link between interactome discovery and clinical translation. To accomplish our goals, we will take a step-wise approach: (1) structural stabilization, (2) directional affinity capture, (3) covalent capture, and (4) binding site identification. Each step will be adapted for high-throughput and validated using proof-of-concept biological experiments. Once identified and catalogued, protein interactions must be validated biologically. A seminal feature of our approach is that the very 1-helices we use to capture the protein interactome can be used to validate and drug the interactions in cellular and in vivo studies. Thus, we believe that engineering stapled peptides for protein capture will create a powerful and versatile approach to elucidating the interactome, and massively expand the potential for discovery of novel interactions and how they impact health and disease. PUBLIC HEALTH RELEVANCE: Protein interactions mediate innumerable cellular activities in health and disease; our goal is to create a transformative high-throughput technology that rapidly and precisely identifies protein targets and their explicit sites of interaction. The novelty of our multidisciplinary approach begins with the chemical recreation of protein substructures that mediate protein interaction, transforming Nature's evolutionarily-honed binding motifs into a discovery toolbox; next, we chemically implant in these bioactive structures molecular functionalities for immobilization and irreversible protein intercalation. By operating at the interface of chemistry, biology, and medicine, we aim to develop and deploy a technology that surmounts the formidable challenge of identifying, distinguishing, and drugging the broad array of human protein targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Conformational Regulation and Therapeutic Targeting of Oncogenic KRAS
  • 批准号:
    10549717
  • 项目类别:
  • 资助金额:
    $47.13万
  • 财政年份:
    2019
  • 负责人:
    Loren David Walensky
  • 依托单位:
Biophysical and Mechanistic Determinants for Cancer Cell Import of Hydrocarbon-Stapled Peptides
  • 批准号:
    9178990
  • 项目类别:
  • 资助金额:
    $19.03万
  • 财政年份:
    2016
  • 负责人:
    Loren David Walensky
  • 依托单位:
Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human Cancer
  • 批准号:
    9321122
  • 项目类别:
  • 资助金额:
    $104.54万
  • 财政年份:
    2015
  • 负责人:
    Loren David Walensky
  • 依托单位:
Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human Cancer
  • 批准号:
    10474551
  • 项目类别:
  • 资助金额:
    $103.12万
  • 财政年份:
    2015
  • 负责人:
    Loren David Walensky
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: